20 articles
A 6-month AI-driven personalized diet intervention cut BMI by 33% and reduced biological age by 8 years in morbidly obese patients.
New England Journal review explores the expanding therapeutic potential of GLP-1 drugs beyond diabetes treatment.
Multi-omic analysis reveals GLP-1 receptor agonists counter aging processes across multiple organ systems and biological pathways.
A noninvasive 13-variable score reveals how fast your liver is aging — and accelerated liver aging raises mortality risk by up to 85%.
Researchers analyzed 2,911 proteins in 50,506 people to create a frailty score that predicts disease risk and biological aging.
A comprehensive 2025 review framework matches GLP-1 agonists, tirzepatide, and other AOMs to specific obesity phenotypes, complications, and life stages.
New study shows DunedinPACE aging biomarker can predict who will develop metabolic syndrome years in advance, outperforming other epigenetic clocks.
Major diabetes organizations call for individualized tech approaches to overcome access barriers and reduce health disparities.
Large study reveals specific blood proteins can identify who will die from heart disease a decade before death occurs.
New research reveals how regular physical activity directly prevents and slows progression of major age-related diseases.
New cryo-EM structures reveal how LYCHOS protein senses cholesterol levels to regulate mTORC1 signaling, offering drug targets for aging.
Major study of 255,000+ people shows optimal cardiovascular health dramatically reduces disease progression and mortality risk.
Diabetes drugs like empagliflozin show surprising anti-aging effects — mimicking caloric restriction and reducing senescent cell burden.
Flavo-Proxylane topical treatment plus ultrasound reduced skin laxity by 44% in people using weight loss medications.
Large NHANES study reveals metabolic syndrome causes measurable acceleration in epigenetic aging clocks, offering new targets for intervention.
Large study of 6,847 patients shows better glucose disposal rates significantly reduce mortality risk in metabolic liver disease.
New research highlights the critical need for culturally tailored digital health tools to improve diabetes management outcomes.
New research shows combining weight-loss medications with hormone therapy could transform health outcomes for obese men with low testosterone.
Scientists developed a comprehensive genetic risk score that outperforms existing tests for predicting metabolic diseases across all ethnicities.
Advanced incretin-based therapies show potential for major weight loss while protecting heart, kidney, liver, and brain health.
